Physician profile
Barry Witt
NPI 1538109699
$1,233.32
in general payments reported to CMS, 2019-2025
12 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2021: $42.19 · 2022: $173 · 2024: $99.91 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $194.62 | 2021-2022 | |
| Covidien LP | $177.61 | 2019 | |
| Ferring Pharmaceuticals INC. | $139.14 | 2019-2025 | Menopur |
| Duchesnay USA Incorporated | $131.25 | 2019 | |
| Abbvie INC. | $124.98 | 2019 | |
| Amag Pharmaceuticals, INC. | $124.14 | 2019 | |
| Sumitomo Pharma America, INC. | $117.32 | 2025 | Gemtesa |
| Galen US INC | $65.05 | 2019 | |
| Emd Serono, INC. | $64.44 | 2019 | |
| Organon LLC | $57.52 | 2024 | |
| Glaxosmithkline, LLC. | $20.11 | 2021 | |
| Merck Sharp & Dohme LLC | $17.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.